Cindy Chan1, Cheng-Wei Wang1, Ching-Hui Chen1,2, Chi-Huang Chen3,4. 1. Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan. 2. Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 3. Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Taipei Medical University Hospital, Taipei, Taiwan. d102095012@gmail.com. 4. Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. d102095012@gmail.com.
Abstract
PURPOSE: To present the first case proposing the use of preimplantation genetic testing for monogeneic disorders for Kallmann syndrome, providing comprehensive care in the genomic era of precision medicine. METHODS: Gonadotropin therapy was used for spermatogenesis, followed by in vitro fertilization by intracytoplasmic sperm injection and embryo transfer. Cross-generational targeted next-generation sequencing was then done for genes known to cause Kallmann syndrome. RESULTS: A heterozygous mutation at codon 102 of the FGFR1 gene was found in the patient, but the father was found to have the same mutation yet is unaffected by Kallmann syndrome. Since no causative mutation was found, a de novo or sporadic mutation was suspected as the cause of Kallmann syndrome in this case. CONCLUSIONS: Comprehensive care must be available for male Kallmann syndrome patients, as treatment should not stop at spermatogenesis, but continue with genetic counseling due to possible inheritance.
PURPOSE: To present the first case proposing the use of preimplantation genetic testing for monogeneic disorders for Kallmann syndrome, providing comprehensive care in the genomic era of precision medicine. METHODS: Gonadotropin therapy was used for spermatogenesis, followed by in vitro fertilization by intracytoplasmic sperm injection and embryo transfer. Cross-generational targeted next-generation sequencing was then done for genes known to cause Kallmann syndrome. RESULTS: A heterozygous mutation at codon 102 of the FGFR1 gene was found in the patient, but the father was found to have the same mutation yet is unaffected by Kallmann syndrome. Since no causative mutation was found, a de novo or sporadic mutation was suspected as the cause of Kallmann syndrome in this case. CONCLUSIONS: Comprehensive care must be available for male Kallmann syndromepatients, as treatment should not stop at spermatogenesis, but continue with genetic counseling due to possible inheritance.
Authors: Jacques Young; Cheng Xu; Georgios E Papadakis; James S Acierno; Luigi Maione; Johanna Hietamäki; Taneli Raivio; Nelly Pitteloud Journal: Endocr Rev Date: 2019-04-01 Impact factor: 19.871
Authors: Ulrich Boehm; Pierre-Marc Bouloux; Mehul T Dattani; Nicolas de Roux; Catherine Dodé; Leo Dunkel; Andrew A Dwyer; Paolo Giacobini; Jean-Pierre Hardelin; Anders Juul; Mohamad Maghnie; Nelly Pitteloud; Vincent Prevot; Taneli Raivio; Manuel Tena-Sempere; Richard Quinton; Jacques Young Journal: Nat Rev Endocrinol Date: 2015-07-21 Impact factor: 43.330
Authors: Flavia Amanda Costa-Barbosa; Ravikumar Balasubramanian; Kimberly W Keefe; Natalie D Shaw; Nada Al-Tassan; Lacey Plummer; Andrew A Dwyer; Cassandra L Buck; Jin-Ho Choi; Stephanie B Seminara; Richard Quinton; Dorota Monies; Brian Meyer; Janet E Hall; Nelly Pitteloud; William F Crowley Journal: J Clin Endocrinol Metab Date: 2013-03-26 Impact factor: 5.958
Authors: Samuel D Quaynor; Maggie E Bosley; Christina G Duckworth; Kelsey R Porter; Soo-Hyun Kim; Hyung-Goo Kim; Lynn P Chorich; Megan E Sullivan; Jeong-Hyeon Choi; Richard S Cameron; Lawrence C Layman Journal: Mol Cell Endocrinol Date: 2016-08-05 Impact factor: 4.102
Authors: Luigi Maione; Andrew A Dwyer; Bruno Francou; Anne Guiochon-Mantel; Nadine Binart; Jérôme Bouligand; Jacques Young Journal: Eur J Endocrinol Date: 2018-01-12 Impact factor: 6.664